AusPAR: Enhertu
Australian Public Assessment Report
Device/Product Name
Enhertu
Active ingredients
Trastuzumab deruxtecan
AusPAR Date
Published
Sponsor
Submission Number
Type C- PM-2022-02867-1-4
Submission Type
Extension of indications
Decision
Approved